Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice

Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice

Aim. To assess efficacy and toxicity of ibrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL). Materials & Methods. In this group of patients ibrutinib has been used since April 2016. Ibrutinib administration criteria were the age > 18 years and the confirmed...

Full description

Bibliographic Details
Main Authors: VI Vorob’ev, VA Zherebtsova, EI Dubrovin, LA Bychenkova, YuB Kochkareva, LA Mukha, VL Ivanova, NK Khuazheva, VV Ptushkin
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2019-03-01
Series:Kliničeskaâ onkogematologiâ
Subjects:
mantle cell lymphoma
ibrutinib
relapse
refractory course
targeted therapy
Online Access: http://bloodjournal.ru/wp-content/uploads/2019/03/6-1.pdf

Internet

http://bloodjournal.ru/wp-content/uploads/2019/03/6-1.pdf

Similar Items